Energy Fuels Inc Ordinary Shares (Canada) vs GeneDx Holdings Corp — how do they compare? Energy Fuels Inc Ordinary Shares (Canada) trades at $8.3 (market cap $2.45B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Energy Fuels Inc Ordinary Shares (Canada) is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Energy Fuels Inc Ordinary Shares (Canada) for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| UUUU | WGS | |
|---|---|---|
Market Cap | $2.45B | $1.94B |
Volume | 7,967,898 | 524,385 |
Sector | Energy | Health |
52-Week High | $27.72 | $167.51 |
52-Week Low | $8.34 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $2.19B | $1.97B |
Signals from Pluang's Aura AI — not financial advice
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →